CHANGCHUNDAXING<08067> - Results Announcement (Q3, 2004, Summary)
Changchun Da Xing Pharmaceutical Company Limited announced on 12/11/2004:
(stock code: 08067 )
Year end date :31/12/2004
Currency :RMB
Auditors' report :N/A
3rd Quarterly Report Reviewed by :Audit Committee
Important Note :
This result announcement form only contains extracted information from
and should be read in conjunction with the detailed results announcement
of the issuer, which can be viewed on the GEM website at
http://www.hkgem.com
(* Unaudited) (* Unaudited)
Current Last Corresponding
Period Period
from 01/01/2004 from 01/01/2003
to 30/09/2004 to 30/09/2003
$'000 $'000
Turnover : 80,117 51,703
Profit/(Loss) from Operations : 40,307 23,682
Finance cost : (2,883) (1,415)
Share of Profit/(Loss) of Associates : N/A N/A
Share of Profit/(Loss) of Jointly
Controlled Entites : N/A N/A
Profit/(Loss) after Taxation & MI : 37,424 22,297
% Change Over the Last Period : +67.84%
EPS / (LPS)
Basic (in dollar) : RMB 0.067 RMB 0.04
Diluted (in dollar) : N/A N/A
Extraordinary (ETD) Gain/(Loss) : N/A N/A
Profit (Loss) after ETD Items : 37,424 22,297
3rd Quarter Dividends per Share : NIL NIL
(specify if with other options) : N/A N/A
B/C Dates for 3rd Quarter Dividends : N/A
Payable Date : N/A
B/C Dates for (-) General Meeting : N/A
Other Distribution for Current Period : NIL
B/C Dates for Other Distribution : N/A
(bdi: both days inclusive)
For and on behalf of
Changchun Da Xing Pharmaceutical Company Limited
Signature :
Name : Yau Wing Yiu
Title : Qualified Accountant
Responsibility statement
The directors of the Company (the "Directors") as at the date hereof
hereby collectively and individually accept full responsibility for the
accuracy of the information contained in this results announcement form
(the "Information") and confirm, having made all reasonable inquiries,
that to the best of their knowledge and belief the Information are
accurate and complete in all material respects and not misleading and
that there are no other matters the omission of which would make the
Information herein inaccurate or misleading.The Directors acknowledge
that the Stock Exchange has no responsibility whatsoever with regard to
the Information and undertake to indemnify the Exchange against all
liability incurred and all losses suffered by the Exchange in connection
with or relating to the Information.
Remarks:
1. Basis of presentation
The Company was incorporated as a joint stock limited company
in the People's Republic of China ("PRC") on 27 December 1993 under
the provisions of the PRC Company Law. The Company's H shares were
listed on the Growth Enterprise Market of The Stock Exchange of
Hong Kong Limited on 28 June 2002.
The Company is principally engaged in the manufacture and sale of
medicine in the PRC.
On 17 January 2003, the Company set up a new company in the PRC,
Changchun Zhong Da Healthcare Product Company Limited
with one of its major shareholders, Changchun Kuancheng Pharmaceutircal
Factory. The company is 60% owned by the Company and 40% by
Changchun Kuancheng Pharmaceutical Factory. The principal activity of
the Company is production of healthcare medication products.
2. Principal accounting policies
The principal accounting policies adopted in preparing the unaudited
consolidated results of the Group conform with the accounting principles
generally accepted in HK and accounting standards issued by
the Hong Kong Institute of Certified Public Accountants.
3. Earnings per share
The calculation of basic earnings per share is based on the
unaudited profit attributable to shareholders for the nine months
ended 30 September 2004 of approximately RMB37,424,000
(2003: RMB 22,297,000) and on the weighted average of 561,000,000
shares in issue during the nine months ended 30 Sepember 2004
(2003: 561,000,000 shares)
4. Dividend
The Board does not recommend the payment of
any interim dividend in respect of the nine months ended
30 Setpember 2004 (2003:Nil)
|